Related Contributions

Lessons from Dimebon
MEMBERS' OPEN FORUM: for rapid-fire posting of your questions and comments.
Shehan De Silva, MJFF
17 Mar 2010
This month, one of the best potential hopes for treating Alzheimer’s disease failed in its first late-stage clinical trial. As a result of a 2008 study, Dimebon, an antihistamine drug approved ... 
Validating PD targets: FK506 binding proteins
POWs: Papers of the Week
Veerle Baekelandt, KU Leuven
02 Mar 2010
I would like to give a response to Mark Frasier’s questions based on our recent paper in J. Neurosci. ... 
For pre-clinical PD models why not look for neuro-protection in pre-clinical pre-motor PD brain regions?
What are the best methods for testing the efficacy of novel neuroprotective therapeutics in pre-clinical models?
Veronica Miller, Wadsworth
24 Feb 2010
There are an abundence of emerging pathological and imaging studies from patients with Lewy Body diseases which strongly suggest that non-dopaminergic neurons are dysfunctional at early ... 
New review on placebo response
What are the biological and psychosocial mechanisms of the placebo response, and how can we manage and/or tap the placebo response in PD clinical trials?
Alison Urkowitz, MJFF, et al.
19 Feb 2010
The recent review by Drs. Finniss, Kaptchuk, Miller and Benedetti of the placebo effect in clinical research explores the mechanistic, clinical and ethical questions that surround this complex ... 
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain
MEMBERS' OPEN FORUM: for rapid-fire posting of your questions and comments.
Piotr Hadaczek, UCSF
09 Feb 2010
Our paper "Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain" has just been accepted for publication in Neuropharmacology. It ... 
Responses: 1
Pharmacokinetics and bioactivity of GDNF and NTN infused into the rat brain
MEMBERS' OPEN FORUM: for rapid-fire posting of your questions and comments.
Piotr Hadaczek, UCSF
19 Feb 2010
 ... 
Placebo Response Workshop: Meeting Take-Aways
What are the biological and psychosocial mechanisms of the placebo response, and how can we manage and/or tap the placebo response in PD clinical trials?
Alison Urkowitz, MJFF, et al.
26 May 2009
Discussion Summary (See a description of the meeting and attendees here) 1.      Current understanding of the placebo response in neurological/psychiatric disorders ... 
Responses: 6
ESC v. iPSC: The difference is in efficiency
Can induced pluripotent stem cells be used to generate useful Parkinson's disease cell models?
Holli Kawadler, MJFF
18 Feb 2010
There are still a number of questions to consider when looking at using iPS in both regenerative medicine and disease modeling, as outlined previously. How similar are ES and iPS cells, can we ... 
Background to the Symposium on Systems Approach to Parkinson’s Disease (SAPD)
Systems Approaches to Parkinson's Disease
Peter Wellstead, Hamilton
17 Feb 2010
The Symposium will cover recent progress in how mathematical and systems analysis methods developed in the physical sciences are being adapted to help understand the complex and unknown biological ... 
A Lentiviral System for Inducible Intracerebroventricular Delivery
MEMBERS' OPEN FORUM: for rapid-fire posting of your questions and comments.
Jamie L Eberling, MJFF
09 Feb 2010
The delivery of synthetic peptides or secreted recombinant proteins to the CNS is often accomplished by intracerebroventricular (ICV) administration. This method is especially problematic for studies ...